{"filing":{"accession_number":"0001193125-26-345733","cik":"0001382101","ticker":"STRO","company_name":"SUTRO BIOPHARMA, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"stro-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1382101/000119312526345733/stro-20260812.htm"},"events":[{"id":27029,"run_id":24598,"accession_number":"0001193125-26-345733","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Sutro Biopharma issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $9.8 million, net loss of $38.5 million, and cash position of $164.3 million, along with early clinical data from the STRO-004 Phase 1 study.","company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28381,"accession_number":"0001193125-26-345733","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sutro Biopharma issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $9.8 million, net loss of $38.5 million, and cash position of $164.3 million. The filing explicitly states \"On August 12, 2026, Sutro Biopharma, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended June 30, 2026\" under Item 2.02, with the press release attached as Exhibit 99.1. This is a standard quarterly earnings release with financial statements and operational highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:19:41.209718+00:00","company_name":"","ticker":null,"filing_date":""},{"id":28382,"accession_number":"0001193125-26-345733","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the primary substantive disclosure is Sutro's second quarter 2026 financial results and early clinical data from the STRO-004 Phase 1 study. EX-99.1 is explicitly titled \"Sutro Biopharma Reports Second Quarter 2026 Financial Results\" and includes detailed financial statements (revenue of $9.8M, net loss of $38.5M, cash position of $164.3M) alongside material clinical updates on the company's lead program. This is a classic earnings release disclosure, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:19:41.209718+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28381,"accession_number":"0001193125-26-345733","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Sutro Biopharma issued a press release on August 12, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $9.8 million, net loss of $38.5 million, and cash position of $164.3 million. The filing explicitly states \"On August 12, 2026, Sutro Biopharma, Inc. (the \"Company\") issued a press release announcing its financial results for the quarter ended June 30, 2026\" under Item 2.02, with the press release attached as Exhibit 99.1. This is a standard quarterly earnings release with financial statements and operational highlights.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:19:41.209718+00:00","company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","filing_date":"2026-08-12"},{"id":28382,"accession_number":"0001193125-26-345733","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1 and EX-99.2) reveal that the primary substantive disclosure is Sutro's second quarter 2026 financial results and early clinical data from the STRO-004 Phase 1 study. EX-99.1 is explicitly titled \"Sutro Biopharma Reports Second Quarter 2026 Financial Results\" and includes detailed financial statements (revenue of $9.8M, net loss of $38.5M, cash position of $164.3M) alongside material clinical updates on the company's lead program. This is a classic earnings release disclosure, material to investors assessing the company's financial condition and clinical progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:19:41.209718+00:00","company_name":"SUTRO BIOPHARMA, INC.","ticker":"STRO","filing_date":"2026-08-12"}]}